Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2021 16:01 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress

Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic Initial Results of RMC-4630-02 Study...
August 04, 2021 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
June 24, 2021 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

REDWOOD CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
June 10, 2021 07:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors

REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
June 02, 2021 07:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
May 18, 2021 07:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
May 10, 2021 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress

Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors; Scientific Publication is First to Demonstrate Anti-Drug Resistance Features Continued Advancement and Enrollment of...
May 03, 2021 07:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

REDWOOD CITY, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
April 21, 2021 07:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development Newly Issued U.S. Patent Further Strengthens RMC-5552 IP Portfolio REDWOOD CITY, Calif., April 21, 2021 (GLOBE...
March 11, 2021 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...